228 related articles for article (PubMed ID: 23238015)
21. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.
Zhou Q; Lui VW; Lau CP; Cheng SH; Ng MH; Cai Y; Chan SL; Yeo W
Biochem Pharmacol; 2012 May; 83(9):1146-58. PubMed ID: 22285225
[TBL] [Abstract][Full Text] [Related]
22. mTOR inhibitors in the treatment of breast cancer.
Vinayak S; Carlson RW
Oncology (Williston Park); 2013 Jan; 27(1):38-44, 46, 48 passim. PubMed ID: 23461041
[TBL] [Abstract][Full Text] [Related]
23. Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer.
Baselga J
Oncologist; 2011; 16 Suppl 1():12-9. PubMed ID: 21278436
[TBL] [Abstract][Full Text] [Related]
24. New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists.
Carraway H; Hidalgo M
Breast Cancer Res; 2004; 6(5):219-24. PubMed ID: 15318929
[TBL] [Abstract][Full Text] [Related]
25. Co-overexpression of Janus kinase 2 and signal transducer and activator of transcription 5a promotes differentiation of mammary cancer cells through reversal of epithelial-mesenchymal transition.
Sultan AS; Brim H; Sherif ZA
Cancer Sci; 2008 Feb; 99(2):272-9. PubMed ID: 18271926
[TBL] [Abstract][Full Text] [Related]
26. [Antihormonal therapy in breast cancer and mTOR inhibitors].
Heudel PÉ; Tredan O; Ray-Coquard I; Treilleux I; Guastalla JP; Bachelot T
Bull Cancer; 2011 Dec; 98(12):1431-7. PubMed ID: 22133994
[TBL] [Abstract][Full Text] [Related]
27. JAK-STAT and JAK-PI3K-mTORC1 pathways regulate telomerase transcriptionally and posttranslationally in ATL cells.
Yamada O; Ozaki K; Akiyama M; Kawauchi K
Mol Cancer Ther; 2012 May; 11(5):1112-21. PubMed ID: 22402124
[TBL] [Abstract][Full Text] [Related]
28. B591, a novel specific pan-PI3K inhibitor, preferentially targets cancer stem cells.
Zhou H; Yu C; Kong L; Xu X; Yan J; Li Y; An T; Gong L; Gong Y; Zhu H; Zhang H; Yang X; Li Y
Oncogene; 2019 May; 38(18):3371-3386. PubMed ID: 30635656
[TBL] [Abstract][Full Text] [Related]
29. The combination of methylsulfonylmethane and tamoxifen inhibits the Jak2/STAT5b pathway and synergistically inhibits tumor growth and metastasis in ER-positive breast cancer xenografts.
S P N; Darvin P; Yoo YB; Joung YH; Kang DY; Kim DN; Hwang TS; Kim SY; Kim WS; Lee HK; Cho BW; Kim HS; Park KD; Park JH; Chang SH; Yang YM
BMC Cancer; 2015 Jun; 15():474. PubMed ID: 26084564
[TBL] [Abstract][Full Text] [Related]
30. Crosstalk between STAT5 activation and PI3K/AKT functions in normal and transformed mammary epithelial cells.
Rädler PD; Wehde BL; Wagner KU
Mol Cell Endocrinol; 2017 Aug; 451():31-39. PubMed ID: 28495456
[TBL] [Abstract][Full Text] [Related]
31. A Novel Covalent mTOR Inhibitor, DHM25, Shows in Vivo Antitumor Activity against Triple-Negative Breast Cancer Cells.
Fouqué A; Delalande O; Jean M; Castellano R; Josselin E; Malleter M; Shoji KF; Hung MD; Rampanarivo H; Collette Y; van de Weghe P; Legembre P
J Med Chem; 2015 Aug; 58(16):6559-73. PubMed ID: 26237138
[TBL] [Abstract][Full Text] [Related]
32. Jak2/Stat5 signaling in mammogenesis, breast cancer initiation and progression.
Wagner KU; Rui H
J Mammary Gland Biol Neoplasia; 2008 Mar; 13(1):93-103. PubMed ID: 18228120
[TBL] [Abstract][Full Text] [Related]
33. ERRα-Regulated Lactate Metabolism Contributes to Resistance to Targeted Therapies in Breast Cancer.
Park S; Chang CY; Safi R; Liu X; Baldi R; Jasper JS; Anderson GR; Liu T; Rathmell JC; Dewhirst MW; Wood KC; Locasale JW; McDonnell DP
Cell Rep; 2016 Apr; 15(2):323-35. PubMed ID: 27050525
[TBL] [Abstract][Full Text] [Related]
34. Repositioning of antibiotic levofloxacin as a mitochondrial biogenesis inhibitor to target breast cancer.
Yu M; Li R; Zhang J
Biochem Biophys Res Commun; 2016 Mar; 471(4):639-45. PubMed ID: 26902121
[TBL] [Abstract][Full Text] [Related]
35. Discovery of novel Jak2-Stat pathway inhibitors with extended residence time on target.
Guan H; Lamb ML; Peng B; Huang S; Degrace N; Read J; Hussain S; Wu J; Rivard C; Alimzhanov M; Bebernitz G; Bell K; Ye M; Zinda M; Ioannidis S
Bioorg Med Chem Lett; 2013 May; 23(10):3105-10. PubMed ID: 23562594
[TBL] [Abstract][Full Text] [Related]
36. Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia.
Tasian SK; Doral MY; Borowitz MJ; Wood BL; Chen IM; Harvey RC; Gastier-Foster JM; Willman CL; Hunger SP; Mullighan CG; Loh ML
Blood; 2012 Jul; 120(4):833-42. PubMed ID: 22685175
[TBL] [Abstract][Full Text] [Related]
37. The JAK2/STAT5 signaling pathway as a potential therapeutic target in canine mastocytoma.
Keller A; Wingelhofer B; Peter B; Bauer K; Berger D; Gamperl S; Reifinger M; Cerny-Reiterer S; Moriggl R; Willmann M; Valent P; Hadzijusufovic E
Vet Comp Oncol; 2018 Mar; 16(1):55-68. PubMed ID: 28397975
[TBL] [Abstract][Full Text] [Related]
38. PI3K inhibition circumvents resistance to SHP2 blockade in metastatic triple-negative breast cancer.
Amante RJ; Jehanno C; De Silva D; Coissieux MM; Ackerknecht M; Romanet V; Sethi A; Hamelin B; Preca BT; Piscuoglio S; Ng CKY; Mohseni M; Bentires-Alj M
J Mammary Gland Biol Neoplasia; 2023 Jun; 28(1):13. PubMed ID: 37294349
[TBL] [Abstract][Full Text] [Related]
39. Silencing growth hormone receptor inhibits estrogen receptor negative breast cancer through ATP-binding cassette sub-family G member 2.
Arumugam A; Subramani R; Nandy SB; Terreros D; Dwivedi AK; Saltzstein E; Lakshmanaswamy R
Exp Mol Med; 2019 Jan; 51(1):1-13. PubMed ID: 30617282
[TBL] [Abstract][Full Text] [Related]
40. SWIM domain protein ZSWIM4 is required for JAK2 inhibition resistance in breast cancer.
Gong K; Song K; Zhu Z; Xiang Q; Wang K; Shi J
Life Sci; 2021 Aug; 279():119696. PubMed ID: 34102191
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
